Chinese sFDA approves Baxter's ADVATE to treat hemophilia A

Baxter International Inc. (NYSE:BAX) today announced the approval of ADVATE [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis of bleeding episodes in individuals with hemophilia A (congenital factor VIII deficiency) in China by the State Food and Drug Administration (SFDA). It is estimated that more than 50,000 people in China are living with hemophilia A.

''The introduction of recombinant FVIII therapies in China offers new treatment options for hemophilia patients. The launch of ADVATE is another step in advancing hemophilia care in China,'' said Professor Yang Renchi, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, the leading professional hematological institution providing basic medical research with clinical services in China.

''Great strides have been made in managing hemophilia, allowing people with this serious condition to live longer, more active and fulfilling lives than ever before,'' said Guan Tao, Secretary General of Hemophilia Home, the hemophilia patient organization in China. ''The availability of ADVATE will be an important milestone for people with hemophilia in China.''

ADVATE is infused directly into the bloodstream and works by temporarily raising the level of factor VIII in the bloodstream, allowing the body's blood clotting process to properly function. Extensive global use and multiple clinical trials demonstrate clinical evidence for ADVATE. With SFDA's action, ADVATE is now approved in 54 countries worldwide.

''The approval of ADVATE in China marks an important milestone for Baxter and supports our ongoing commitment to treating individuals living with hemophilia,'' said Ludwig Hantson, Ph.D., president of Baxter's BioScience business.

Baxter continues to work closely with the Chinese hemophilia community, including both patients and treaters, to provide access to care for this life-saving, life-sustaining therapy. In 2010, Baxter cooperated with the Ministry of Health to set up a ''Hemophilia Disease Management System,'' China's first nationwide hemophilia patient registration and management system integrating diagnosis and treatment information. In recent years, Baxter has donated more than five million IUs of hemophilia products to Chinese patients and has provided a number of resources to raise awareness of the disease.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Baxter International Inc.. (2019, June 24). Chinese sFDA approves Baxter's ADVATE to treat hemophilia A. News-Medical. Retrieved on July 17, 2024 from https://www.news-medical.net/news/20120517/Chinese-sFDA-approves-Baxters-ADVATE-to-treat-hemophilia-A.aspx.

  • MLA

    Baxter International Inc.. "Chinese sFDA approves Baxter's ADVATE to treat hemophilia A". News-Medical. 17 July 2024. <https://www.news-medical.net/news/20120517/Chinese-sFDA-approves-Baxters-ADVATE-to-treat-hemophilia-A.aspx>.

  • Chicago

    Baxter International Inc.. "Chinese sFDA approves Baxter's ADVATE to treat hemophilia A". News-Medical. https://www.news-medical.net/news/20120517/Chinese-sFDA-approves-Baxters-ADVATE-to-treat-hemophilia-A.aspx. (accessed July 17, 2024).

  • Harvard

    Baxter International Inc.. 2019. Chinese sFDA approves Baxter's ADVATE to treat hemophilia A. News-Medical, viewed 17 July 2024, https://www.news-medical.net/news/20120517/Chinese-sFDA-approves-Baxters-ADVATE-to-treat-hemophilia-A.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Gilead to boost price of new hepatitis c drug